Abstract: To provide an oxide semiconductor film having stable electric conductivity and a highly reliable semiconductor device having stable electric characteristics by using the oxide semiconductor film. The oxide semiconductor film contains indium (In), gallium (Ga), and zinc (Zn) and includes a c-axis-aligned crystalline region aligned in the direction parallel to a normal vector of a surface where the oxide semiconductor film is formed. Further, the composition of the c-axis-aligned crystalline region is represented by In1+?Ga1??O3(ZnO)m (0<?<1 and m=1 to 3 are satisfied), and the composition of the entire oxide semiconductor film including the c-axis-aligned crystalline region is represented by InxGayO3(ZnO)m (0<x<2, 0<y<2, and m=1 to 3 are satisfied).

Abstract: Crystalline particles of N-(17-cyclopropylmethyl-4,5?-epoxy-3,14-dihydroxy-morphinan-6?-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 ?m, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 ?m, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.

Abstract: The present invention is directed to provide 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride consistent in quality after production and having high purity. A crystal of 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride including a A-form, B-form or C-form crystal thereof, and a process for producing the same are provided.

Abstract: Crystalline particles of N-(17-cyclopropylmethyl-4,5?-epoxy-3,14-dihydroxy-morphinan-6?-yl)-phthalimide or a pharmaceutically acceptable salt thereof are disclosed. The crystalline particles have a particle diameter distribution in which a particle diameter (D50) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 50% is within a range of 1 to 30 ?m, and a particle diameter (D90) at the point where cumulative frequency of volume distribution cumulatively calculated from particles having a smaller diameter reaches 90% is not more than 90 ?m, which crystalline particles have a degree of crystallinity of not less than 80%. By the crystalline particles, bioavailability of the active substance may be increased while ensuring storage stability of the compound.

Abstract: A method of treating sludge or wastewater involving the following steps: a swelling step which prepares a swelling liquid by adding a powdery polymer flocculant to water; a dissolution step which obtains an aqueous flocculant solution by supplying the swelling liquid to a filtration component and passing a filtering area of the filtration component; a flocculation treatment step which adds the aqueous flocculant solution to sludge or wastewater, wherein the total processing time from the time point where the powdery polymer flocculant was added to water until just before adding to sludge or wastewater to the aqueous flocculant solution is less than 3 hours.

Abstract: The present invention is directed to provide 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride consistent in quality after production and having high purity. A crystal of 17-cyclopropylmethyl-3,14?-dihydroxy-4,5?-epoxy-6?-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride including a A-form, B-form or C-form crystal thereof, and a process for producing the same are provided.

Abstract: A freeze-dried product containing a platinum (II) complex represented by the following general formula as a primary component.

Abstract: A process for surface-treating a body made of metal is disclosed, which includes a step of immersing the body made of metal in an aqueous solution containing at least one organometallic compound and at least one film-forming assistant, thereby forming a transparent film on a surface of the body made of metal. Further, in accordance with the present invention, there is provided a composition of matter including a substrate made of magnesium or a magnesium alloy and a transparent film formed on the substrate, which can be prepared by the process.

Abstract: A process for surface-treating a body made of metal is disclosed, which includes a step of immersing the body made of metal in an aqueous solution containing at least one organometallic compound and at least one film-forming assistant, thereby forming a transparent film on a surface of the body made of metal. Further, in accordance with the present invention, there is provided a composition of matter including a substrate made of magnesium or a magnesium alloy and a transparent film formed on the substrate, which can be prepared by the process.

Abstract: A process for surface-treating a body made of metal is disclosed, which includes a step of immersing the body made of metal in an aqueous solution containing at least one organometallic compound and at least one film-forming assistant, thereby forming a transparent film on a surface of the body made of metal. Further, in accordance with the present invention, there is provided a composition of matter including a substrate made of magnesium or a magnesium alloy and a transparent film formed on the substrate, which can be prepared by the process.

Abstract: A method for surface-treating a substrate made of a magnesium-based metal material is disclosed, which includes immersing the substrate in an electrolyte composed of an aqueous solution containing at least one component selected from the group consisting of hydroxides, carbonates and bicarbonates of alkali metals or alkali earth metals, and a film-forming stabilizer, and conducting an electrolysis to form an anodic oxide film on a surface of the substrate. The film-forming stabilizer includes one component selected from salts of mineral acids, fluorides, silicates and silicofluorides and an additional component selected from ethylene glycol, trihydroxypropane, dihydroxyethyl ether and sodium hydroxybenzoate. Further, in accordance with the present invention, there is provided the substrate which is surface-treated by the method.

Abstract: A suturing instrument for a surgical operation includes a suturing portion having a base, a vertically reciprocating needle holder carrying a needle with an upper thread, a device for supplying a predetermined amount of the upper thread to the needle and a loop taker supported in the base for turnable movement relative thereto and operative for catching a thread loop formed on the needle. The device for supplying the upper thread, the loop taker and the needle holder are activated for sequential operation by a control portion of the instrument which includes a fluid drive device connected to the suturing portion and including a plurality of hydraulic cylinders. The control portion is activated by a manually operated switch which actuates an electric circuit and a switching device operating a plurality of the cylinders for sequentially imparting the reciprocating movements to the needle, the loop taker and the thread supplying device.